Cancer-associated fibroblast-derived lactate drives cholangiocarcinoma progression via H4K12la-mediated oxidative phosphorylation activation
Clinical and Molecular Hepatology · 17.11.2026
DOI: 10.3350/cmh.2026.0591 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, online erschienen am 17.11.2026. Verfasst von Xiao Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Nanjing Medical University; Key Laboratory for Liver Transplantation, Chinese A….
Abstract (Originalsprache)
Background
Cholangiocarcinoma (CCA) is a highly aggressive malignancy, and chemoresistance is a major cause of poor prognosis. This study aimed to elucidate the molecular mechanisms driving CCA progression from a tumor microenvironment perspective and to develop novel strategies to enhance chemosensitivity.
Methods
Single-cell RNA-seq, untargeted metabolomics, and proteomics were used to identify the source of lactate in the CCA microenvironment and the metabolic reprogramming of cancer-associated fibroblasts (CAFs). To evaluate the impact of CAF-derived lactate on prognosis, we performed AAV-mediated MCT4 knockdown followed by hydrodynamic injection to induce a CCA model. Co-culture models were combined with genome-wide CUT&Tag, MeRIP-seq, and RIP-seq to resolve epigenetic and post-transcriptional regulatory mechanisms. The antitumor effects of 7ACC1 (a small molecule reported to inhibit lactate uptake), alone or in combination with gemcitabine, were assessed in subcutaneous and orthotopic liver xenograft models.
Results
CAFs undergo glycolytic reprogramming, resulting in aberrant lactate accumulation. Mechanistically, CAF-derived lactate induces H4K12 lactylation (H4K12la) in CCA cells, which in turn activates the IGF2BP3/ATF3 axis to upregulate oxidative phosphorylation and promote tumor progression. The lactate shuttle inhibitor 7ACC1, combined with gemcitabine, exerts promising antitumor effects. Clinically, high levels of MCT4, α SMA, and H4K12la are associated with poor prognosis in patients with CCA.
Conclusions
These findings reveal that CAFs drive CCA progression via lactate-induced H4K12la, which activates the IGF2BP3/ATF3 axis. The findings provide a preclinical rationale for further evaluation of lactate-uptake-targeting strategies in combination with gemcitabine for CCA.
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, The First Affiliated Hospital of Nanjing Medical University; Key Laboratory for Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver T…
- Department of General Surgery, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, Jiangsu Province, 214023, China.
- Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province, 210029, China. drchenyan@stu.njmu.edu.cn.
- Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, 210029, China. drlcx@njmu.edu.cn.
- Department of General Surgery, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, Jiangsu Province, 214023, China. drxcli@…
- Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, 210029, China. drxcli@njmu.edu.cn.
Zitieren
APA
Xu, X., Chen, Y., Wang, Z., Liu, S., Cui, J., Shao, S., Cao, K., Zhang, J., Li, C., & Li, X. (2026). Cancer-associated fibroblast-derived lactate drives cholangiocarcinoma progression via H4K12la-mediated oxidative phosphorylation activation. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2026.0591
Vancouver
Xu X, Chen Y, Wang Z, Liu S, Cui J, Shao S, et al. Cancer-associated fibroblast-derived lactate drives cholangiocarcinoma progression via H4K12la-mediated oxidative phosphorylation activation. Clinical and Molecular Hepatology. 2026. doi:10.3350/cmh.2026.0591
BibTeX
@article{Xu2026,
author = {Xu, Xiao and Chen, Yananlan and Wang, Ziyang and Liu, Shuochen and Cui, Ji and Shao, Shenye and Cao, Kai and Zhang, Jiawei and Li, Changxian and Li, Xiangcheng},
title = {Cancer-associated fibroblast-derived lactate drives cholangiocarcinoma progression via H4K12la-mediated oxidative phosphorylation activation},
journal = {Clinical and Molecular Hepatology},
year = {2026},
doi = {10.3350/cmh.2026.0591}
}
EUVIMED